#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Treatments for Diabetic Foot Ulcers
2-1	4-14	Treatments	abstract[2]	new[2]	coref	9-5[82_2]
2-2	15-18	for	abstract[2]	new[2]	_	_
2-3	19-27	Diabetic	abstract[2]|abstract|abstract[5]	new[2]|new|new[5]	coref|coref	11-3|11-3
2-4	28-32	Foot	abstract[2]|person|abstract[5]	new[2]|new|new[5]	_	_
2-5	33-39	Ulcers	abstract[2]|abstract[5]	new[2]|new[5]	_	_

#Text=One strategy for the management of patients with a DFU is to introduce a multidisciplinary approach and address the multifactorial processes involved in DFUs .
3-1	40-43	One	abstract[6]	new[6]	_	_
3-2	44-52	strategy	abstract[6]	new[6]	_	_
3-3	53-56	for	abstract[6]	new[6]	_	_
3-4	57-60	the	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-5	61-71	management	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-6	72-74	of	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-7	75-83	patients	abstract[6]|abstract[7]|person[8]	new[6]|new[7]|new[8]	coref	4-65[33_8]
3-8	84-88	with	abstract[6]|abstract[7]|person[8]	new[6]|new[7]|new[8]	_	_
3-9	89-90	a	abstract[6]|abstract[7]|person[8]|abstract[9]	new[6]|new[7]|new[8]|new[9]	coref	13-13[96_9]
3-10	91-94	DFU	abstract[6]|abstract[7]|person[8]|abstract[9]	new[6]|new[7]|new[8]|new[9]	_	_
3-11	95-97	is	_	_	_	_
3-12	98-100	to	_	_	_	_
3-13	101-110	introduce	_	_	_	_
3-14	111-112	a	abstract[10]	new[10]	_	_
3-15	113-130	multidisciplinary	abstract[10]	new[10]	_	_
3-16	131-139	approach	abstract[10]	new[10]	_	_
3-17	140-143	and	_	_	_	_
3-18	144-151	address	_	_	_	_
3-19	152-155	the	abstract[11]	new[11]	_	_
3-20	156-170	multifactorial	abstract[11]	new[11]	_	_
3-21	171-180	processes	abstract[11]	new[11]	_	_
3-22	181-189	involved	_	_	_	_
3-23	190-192	in	_	_	_	_
3-24	193-197	DFUs	event	new	coref	4-44
3-25	198-199	.	_	_	_	_

#Text=The use of multi-disciplinary teams ( MDTs ) that include all relevant specialties ( i. e. , nursing , orthopedics , plastic surgery , vascular surgery , nutrition , and endocrinology departments ) has shown an effect of decreasing the risks associated with DFUs and amputation by 50 – 85 % , lowering costs , and leading to a better quality of life for patients with DFUs .
4-1	200-203	The	abstract[13]	new[13]	_	_
4-2	204-207	use	abstract[13]	new[13]	_	_
4-3	208-210	of	abstract[13]	new[13]	_	_
4-4	211-229	multi-disciplinary	abstract[13]|organization[14]	new[13]|new[14]	_	_
4-5	230-235	teams	abstract[13]|organization[14]	new[13]|new[14]	_	_
4-6	236-237	(	_	_	_	_
4-7	238-242	MDTs	abstract	new	_	_
4-8	243-244	)	_	_	_	_
4-9	245-249	that	_	_	_	_
4-10	250-257	include	_	_	_	_
4-11	258-261	all	event[16]	new[16]	appos	4-18[0_16]
4-12	262-270	relevant	event[16]	new[16]	_	_
4-13	271-282	specialties	event[16]	new[16]	_	_
4-14	283-284	(	_	_	_	_
4-15	285-287	i.	_	_	_	_
4-16	288-290	e.	_	_	_	_
4-17	291-292	,	_	_	_	_
4-18	293-300	nursing	abstract	giv	appos	4-22[19_0]
4-19	301-302	,	_	_	_	_
4-20	303-314	orthopedics	_	_	_	_
4-21	315-316	,	_	_	_	_
4-22	317-324	plastic	substance|event[19]	new|giv[19]	appos|appos	4-25[20_19]|4-25[20_19]
4-23	325-332	surgery	event[19]	giv[19]	_	_
4-24	333-334	,	_	_	_	_
4-25	335-343	vascular	event[20]	giv[20]	_	_
4-26	344-351	surgery	event[20]	giv[20]	_	_
4-27	352-353	,	_	_	_	_
4-28	354-363	nutrition	abstract	new	_	_
4-29	364-365	,	_	_	_	_
4-30	366-369	and	_	_	_	_
4-31	370-383	endocrinology	abstract|organization[23]	new|new[23]	_	_
4-32	384-395	departments	organization[23]	new[23]	_	_
4-33	396-397	)	_	_	_	_
4-34	398-401	has	_	_	_	_
4-35	402-407	shown	_	_	_	_
4-36	408-410	an	abstract[24]	new[24]	coref	21-3[154_24]
4-37	411-417	effect	abstract[24]	new[24]	_	_
4-38	418-420	of	_	_	_	_
4-39	421-431	decreasing	_	_	_	_
4-40	432-435	the	abstract[25]	new[25]	_	_
4-41	436-441	risks	abstract[25]	new[25]	_	_
4-42	442-452	associated	_	_	_	_
4-43	453-457	with	_	_	_	_
4-44	458-462	DFUs	abstract	giv	coref	4-67
4-45	463-466	and	_	_	_	_
4-46	467-477	amputation	abstract[27]	new[27]	_	_
4-47	478-480	by	abstract[27]	new[27]	_	_
4-48	481-483	50	abstract[27]|quantity[29]	new[27]|new[29]	_	_
4-49	484-485	–	abstract[27]|quantity[29]	new[27]|new[29]	_	_
4-50	486-488	85	abstract[27]|quantity|quantity[29]	new[27]|new|new[29]	_	_
4-51	489-490	%	abstract[27]|quantity[29]	new[27]|new[29]	_	_
4-52	491-492	,	_	_	_	_
4-53	493-501	lowering	_	_	_	_
4-54	502-507	costs	abstract	new	_	_
4-55	508-509	,	_	_	_	_
4-56	510-513	and	_	_	_	_
4-57	514-521	leading	_	_	_	_
4-58	522-524	to	_	_	_	_
4-59	525-526	a	abstract[31]	new[31]	_	_
4-60	527-533	better	abstract[31]	new[31]	_	_
4-61	534-541	quality	abstract[31]	new[31]	_	_
4-62	542-544	of	abstract[31]	new[31]	_	_
4-63	545-549	life	abstract[31]|abstract	new[31]|new	_	_
4-64	550-553	for	abstract[31]	new[31]	_	_
4-65	554-562	patients	abstract[31]|person[33]	new[31]|giv[33]	coref	13-27[100_33]
4-66	563-567	with	abstract[31]|person[33]	new[31]|giv[33]	_	_
4-67	568-572	DFUs	abstract[31]|person[33]|abstract	new[31]|giv[33]|giv	coref	5-3
4-68	573-574	.	_	_	_	_

#Text=Management of DFUs requires the correct classification of stage and severity .
5-1	575-585	Management	abstract[35]	new[35]	coref	14-13[107_35]
5-2	586-588	of	abstract[35]	new[35]	_	_
5-3	589-593	DFUs	abstract[35]|abstract	new[35]|giv	coref	6-4
5-4	594-602	requires	_	_	_	_
5-5	603-606	the	abstract[37]	new[37]	_	_
5-6	607-614	correct	abstract[37]	new[37]	_	_
5-7	615-629	classification	abstract[37]	new[37]	_	_
5-8	630-632	of	abstract[37]	new[37]	_	_
5-9	633-638	stage	abstract[37]|abstract	new[37]|new	_	_
5-10	639-642	and	abstract[37]	new[37]	_	_
5-11	643-651	severity	abstract[37]|abstract	new[37]|new	_	_
5-12	652-653	.	_	_	_	_

#Text=Adequate care for DFUs should include a focus on DM control as well as on wound care , proper infection control , relieving pressure , and optimizing blood flow .
6-1	654-662	Adequate	abstract[40]	new[40]	_	_
6-2	663-667	care	abstract[40]	new[40]	_	_
6-3	668-671	for	abstract[40]	new[40]	_	_
6-4	672-676	DFUs	abstract[40]|event	new[40]|giv	coref	7-10
6-5	677-683	should	_	_	_	_
6-6	684-691	include	_	_	_	_
6-7	692-693	a	abstract[42]	new[42]	_	_
6-8	694-699	focus	abstract[42]	new[42]	_	_
6-9	700-702	on	abstract[42]	new[42]	_	_
6-10	703-705	DM	abstract[42]|person|abstract[44]	new[42]|new|new[44]	coref|coref	6-19[48_44]|6-19[48_44]
6-11	706-713	control	abstract[42]|abstract[44]	new[42]|new[44]	_	_
6-12	714-716	as	_	_	_	_
6-13	717-721	well	_	_	_	_
6-14	722-724	as	_	_	_	_
6-15	725-727	on	_	_	_	_
6-16	728-733	wound	abstract|abstract[46]	new|new[46]	coref|coref|coref|coref	7-1[51_46]|8-25|7-1[51_46]|8-25
6-17	734-738	care	abstract[46]	new[46]	_	_
6-18	739-740	,	_	_	_	_
6-19	741-747	proper	abstract[48]	giv[48]	coref	7-5[52_48]
6-20	748-757	infection	abstract|abstract[48]	new|giv[48]	coref	7-25
6-21	758-765	control	abstract[48]	giv[48]	_	_
6-22	766-767	,	_	_	_	_
6-23	768-777	relieving	_	_	_	_
6-24	778-786	pressure	abstract	new	coref	7-20
6-25	787-788	,	_	_	_	_
6-26	789-792	and	_	_	_	_
6-27	793-803	optimizing	_	_	_	_
6-28	804-809	blood	abstract[50]	new[50]	_	_
6-29	810-814	flow	abstract[50]	new[50]	_	_
6-30	815-816	.	_	_	_	_

#Text=The basic care for the control and treatment of DFUs is focused on the management of adequate perfusion , pressure mitigation , control of infection , and debridement .
7-1	817-820	The	abstract[51]	giv[51]	coref	19-34[0_51]
7-2	821-826	basic	abstract[51]	giv[51]	_	_
7-3	827-831	care	abstract[51]	giv[51]	_	_
7-4	832-835	for	abstract[51]	giv[51]	_	_
7-5	836-839	the	abstract[51]|abstract[52]	giv[51]|giv[52]	coref	7-23[59_52]
7-6	840-847	control	abstract[51]|abstract[52]	giv[51]|giv[52]	_	_
7-7	848-851	and	abstract[51]	giv[51]	_	_
7-8	852-861	treatment	abstract[51]|abstract[53]	giv[51]|new[53]	coref	18-1[123_53]
7-9	862-864	of	abstract[51]|abstract[53]	giv[51]|new[53]	_	_
7-10	865-869	DFUs	abstract[51]|abstract[53]|abstract	giv[51]|new[53]|giv	coref	8-10
7-11	870-872	is	_	_	_	_
7-12	873-880	focused	_	_	_	_
7-13	881-883	on	_	_	_	_
7-14	884-887	the	person[55]	new[55]	_	_
7-15	888-898	management	person[55]	new[55]	_	_
7-16	899-901	of	person[55]	new[55]	_	_
7-17	902-910	adequate	person[55]|substance[56]	new[55]|new[56]	_	_
7-18	911-920	perfusion	person[55]|substance[56]	new[55]|new[56]	_	_
7-19	921-922	,	person[55]	new[55]	_	_
7-20	923-931	pressure	person[55]|abstract|abstract[58]	new[55]|giv|new[58]	coref|coref	8-24|8-24
7-21	932-942	mitigation	person[55]|abstract[58]	new[55]|new[58]	_	_
7-22	943-944	,	person[55]	new[55]	_	_
7-23	945-952	control	person[55]|abstract[59]	new[55]|giv[59]	coref	14-1[103_59]
7-24	953-955	of	person[55]|abstract[59]	new[55]|giv[59]	_	_
7-25	956-965	infection	person[55]|abstract[59]|event	new[55]|giv[59]|giv	_	_
7-26	966-967	,	person[55]	new[55]	_	_
7-27	968-971	and	person[55]	new[55]	_	_
7-28	972-983	debridement	person[55]|abstract	new[55]|new	_	_
7-29	984-985	.	_	_	_	_

#Text=With technological advancement , other series of therapies for DFUs have been implemented , such as the development of skin substitutes , negative pressure wound therapy , hyperbaric oxygen , the creation of new wound dressings that include growth factors , and the use of tissues from bioengineering .
8-1	986-990	With	_	_	_	_
8-2	991-1004	technological	abstract[62]	new[62]	_	_
8-3	1005-1016	advancement	abstract[62]	new[62]	_	_
8-4	1017-1018	,	_	_	_	_
8-5	1019-1024	other	abstract[63]	new[63]	_	_
8-6	1025-1031	series	abstract[63]	new[63]	_	_
8-7	1032-1034	of	abstract[63]	new[63]	_	_
8-8	1035-1044	therapies	abstract[63]|abstract[64]	new[63]|new[64]	coref	28-1[209_64]
8-9	1045-1048	for	abstract[63]|abstract[64]	new[63]|new[64]	_	_
8-10	1049-1053	DFUs	abstract[63]|abstract[64]|abstract	new[63]|new[64]|giv	_	_
8-11	1054-1058	have	_	_	_	_
8-12	1059-1063	been	_	_	_	_
8-13	1064-1075	implemented	_	_	_	_
8-14	1076-1077	,	_	_	_	_
8-15	1078-1082	such	_	_	_	_
8-16	1083-1085	as	_	_	_	_
8-17	1086-1089	the	abstract[66]	new[66]	_	_
8-18	1090-1101	development	abstract[66]	new[66]	_	_
8-19	1102-1104	of	abstract[66]	new[66]	_	_
8-20	1105-1109	skin	abstract[66]|object|object[68]	new[66]|new|new[68]	_	_
8-21	1110-1121	substitutes	abstract[66]|object[68]	new[66]|new[68]	_	_
8-22	1122-1123	,	abstract[66]	new[66]	_	_
8-23	1124-1132	negative	abstract[66]|abstract[71]	new[66]|new[71]	coref	19-1[133_71]
8-24	1133-1141	pressure	abstract[66]|abstract|abstract[71]	new[66]|giv|new[71]	_	_
8-25	1142-1147	wound	abstract[66]|abstract|abstract[71]	new[66]|giv|new[71]	coref	8-35
8-26	1148-1155	therapy	abstract[66]|abstract[71]	new[66]|new[71]	_	_
8-27	1156-1157	,	abstract[66]	new[66]	_	_
8-28	1158-1168	hyperbaric	abstract[66]|substance[72]	new[66]|new[72]	_	_
8-29	1169-1175	oxygen	abstract[66]|substance[72]	new[66]|new[72]	_	_
8-30	1176-1177	,	_	_	_	_
8-31	1178-1181	the	abstract[73]	new[73]	_	_
8-32	1182-1190	creation	abstract[73]	new[73]	_	_
8-33	1191-1193	of	abstract[73]	new[73]	_	_
8-34	1194-1197	new	abstract[73]|object[75]	new[73]|new[75]	_	_
8-35	1198-1203	wound	abstract[73]|abstract|object[75]	new[73]|giv|new[75]	_	_
8-36	1204-1213	dressings	abstract[73]|object[75]	new[73]|new[75]	_	_
8-37	1214-1218	that	_	_	_	_
8-38	1219-1226	include	_	_	_	_
8-39	1227-1233	growth	abstract|abstract[77]	new|new[77]	coref|coref	28-7[211_77]|28-7[211_77]
8-40	1234-1241	factors	abstract[77]	new[77]	_	_
8-41	1242-1243	,	_	_	_	_
8-42	1244-1247	and	_	_	_	_
8-43	1248-1251	the	abstract[78]	new[78]	_	_
8-44	1252-1255	use	abstract[78]	new[78]	_	_
8-45	1256-1258	of	abstract[78]	new[78]	_	_
8-46	1259-1266	tissues	abstract[78]|substance[79]	new[78]|new[79]	_	_
8-47	1267-1271	from	abstract[78]|substance[79]	new[78]|new[79]	_	_
8-48	1272-1286	bioengineering	abstract[78]|substance[79]|person	new[78]|new[79]|new	_	_
8-49	1287-1288	.	_	_	_	_

#Text=In this way , treatments for DPN , PAD , and infections have provided encouraging results .
9-1	1289-1291	In	_	_	_	_
9-2	1292-1296	this	abstract[81]	new[81]	_	_
9-3	1297-1300	way	abstract[81]	new[81]	_	_
9-4	1301-1302	,	_	_	_	_
9-5	1303-1313	treatments	abstract[82]	giv[82]	coref	11-1[88_82]
9-6	1314-1317	for	abstract[82]	giv[82]	_	_
9-7	1318-1321	DPN	abstract[82]|abstract	giv[82]|new	coref	13-1
9-8	1322-1323	,	abstract[82]	giv[82]	_	_
9-9	1324-1327	PAD	abstract[82]|place	giv[82]|new	_	_
9-10	1328-1329	,	abstract[82]	giv[82]	_	_
9-11	1330-1333	and	abstract[82]	giv[82]	_	_
9-12	1334-1344	infections	abstract[82]|abstract	giv[82]|new	_	_
9-13	1345-1349	have	_	_	_	_
9-14	1350-1358	provided	_	_	_	_
9-15	1359-1370	encouraging	_	_	_	_
9-16	1371-1378	results	abstract	new	_	_
9-17	1379-1380	.	_	_	_	_

#Text=4.1 .
10-1	1381-1384	4.1	abstract	new	_	_
10-2	1385-1386	.	_	_	_	_

#Text=Treatments for Diabetic Peripheral
11-1	1387-1397	Treatments	abstract[88]	giv[88]	coref	18-23[126_88]
11-2	1398-1401	for	abstract[88]	giv[88]	_	_
11-3	1402-1410	Diabetic	abstract[88]|abstract|abstract[90]	giv[88]|giv|new[90]	_	_
11-4	1411-1421	Peripheral	abstract[88]|abstract[90]	giv[88]|new[90]	_	_

#Text=Neuropathy
12-1	1422-1432	Neuropathy	abstract	new	coref	16-9[114_0]

#Text=DPN is a factor that increases the risk of the appearance of a DFU , owing to the loss of sensation in the limb , making patients vulnerable to trauma .
13-1	1433-1436	DPN	abstract	giv	coref	13-3[93_0]
13-2	1437-1439	is	_	_	_	_
13-3	1440-1441	a	abstract[93]	giv[93]	coref	14-13[0_93]
13-4	1442-1448	factor	abstract[93]	giv[93]	_	_
13-5	1449-1453	that	_	_	_	_
13-6	1454-1463	increases	_	_	_	_
13-7	1464-1467	the	abstract[94]	new[94]	_	_
13-8	1468-1472	risk	abstract[94]	new[94]	_	_
13-9	1473-1475	of	abstract[94]	new[94]	_	_
13-10	1476-1479	the	abstract[94]|abstract[95]	new[94]|new[95]	_	_
13-11	1480-1490	appearance	abstract[94]|abstract[95]	new[94]|new[95]	_	_
13-12	1491-1493	of	abstract[94]|abstract[95]	new[94]|new[95]	_	_
13-13	1494-1495	a	abstract[94]|abstract[95]|event[96]	new[94]|new[95]|giv[96]	coref	33-69[257_96]
13-14	1496-1499	DFU	abstract[94]|abstract[95]|event[96]	new[94]|new[95]|giv[96]	_	_
13-15	1500-1501	,	_	_	_	_
13-16	1502-1507	owing	_	_	_	_
13-17	1508-1510	to	_	_	_	_
13-18	1511-1514	the	abstract[97]	new[97]	_	_
13-19	1515-1519	loss	abstract[97]	new[97]	_	_
13-20	1520-1522	of	abstract[97]	new[97]	_	_
13-21	1523-1532	sensation	abstract[97]|abstract[98]	new[97]|new[98]	_	_
13-22	1533-1535	in	abstract[97]|abstract[98]	new[97]|new[98]	_	_
13-23	1536-1539	the	abstract[97]|abstract[98]|object[99]	new[97]|new[98]|new[99]	_	_
13-24	1540-1544	limb	abstract[97]|abstract[98]|object[99]	new[97]|new[98]|new[99]	_	_
13-25	1545-1546	,	_	_	_	_
13-26	1547-1553	making	_	_	_	_
13-27	1554-1562	patients	person[100]	giv[100]	coref	16-12[115_100]
13-28	1563-1573	vulnerable	person[100]	giv[100]	_	_
13-29	1574-1576	to	_	_	_	_
13-30	1577-1583	trauma	event	new	_	_
13-31	1584-1585	.	_	_	_	_

#Text=Tight glycemic control is the primary step and a main feature of DPN management .
14-1	1586-1591	Tight	abstract[103]	giv[103]	coref	14-5[104_103]
14-2	1592-1600	glycemic	abstract|abstract[103]	new|giv[103]	_	_
14-3	1601-1608	control	abstract[103]	giv[103]	_	_
14-4	1609-1611	is	_	_	_	_
14-5	1612-1615	the	abstract[104]	giv[104]	_	_
14-6	1616-1623	primary	abstract[104]	giv[104]	_	_
14-7	1624-1628	step	abstract[104]	giv[104]	_	_
14-8	1629-1632	and	abstract[104]	giv[104]	_	_
14-9	1633-1634	a	abstract[104]|abstract[105]	giv[104]|new[105]	_	_
14-10	1635-1639	main	abstract[104]|abstract[105]	giv[104]|new[105]	_	_
14-11	1640-1647	feature	abstract[104]|abstract[105]	giv[104]|new[105]	_	_
14-12	1648-1650	of	abstract[104]|abstract[105]	giv[104]|new[105]	_	_
14-13	1651-1654	DPN	abstract[104]|abstract[105]|abstract|abstract[107]	giv[104]|new[105]|giv|giv[107]	coref|coref|coref|coref	16-14|20-21[152_107]|16-14|20-21[152_107]
14-14	1655-1665	management	abstract[104]|abstract[105]|abstract[107]	giv[104]|new[105]|giv[107]	_	_
14-15	1666-1667	.	_	_	_	_

#Text=Normoglycemia is more effectively restored by a pancreas transplant .
15-1	1668-1681	Normoglycemia	place	new	_	_
15-2	1682-1684	is	_	_	_	_
15-3	1685-1689	more	_	_	_	_
15-4	1690-1701	effectively	_	_	_	_
15-5	1702-1710	restored	_	_	_	_
15-6	1711-1713	by	_	_	_	_
15-7	1714-1715	a	event[110]	new[110]	coref	16-20[119_110]
15-8	1716-1724	pancreas	object|event[110]	new|new[110]	coref	16-21
15-9	1725-1735	transplant	event[110]	new[110]	_	_
15-10	1736-1737	.	_	_	_	_

#Text=Several studies have demonstrated improvement of motor and sensory neuropathy in patients with DPN after they were treated with a pancreas transplant .
16-1	1738-1745	Several	event[111]	new[111]	coref	22-8[158_111]
16-2	1746-1753	studies	event[111]	new[111]	_	_
16-3	1754-1758	have	_	_	_	_
16-4	1759-1771	demonstrated	_	_	_	_
16-5	1772-1783	improvement	abstract[112]	new[112]	coref	25-37[191_112]
16-6	1784-1786	of	abstract[112]	new[112]	_	_
16-7	1787-1792	motor	abstract[112]|object	new[112]|new	_	_
16-8	1793-1796	and	abstract[112]	new[112]	_	_
16-9	1797-1804	sensory	abstract[112]|abstract[114]	new[112]|giv[114]	coref	25-29[0_114]
16-10	1805-1815	neuropathy	abstract[112]|abstract[114]	new[112]|giv[114]	_	_
16-11	1816-1818	in	abstract[112]|abstract[114]	new[112]|giv[114]	_	_
16-12	1819-1827	patients	abstract[112]|abstract[114]|person[115]	new[112]|giv[114]|giv[115]	ana	16-16[0_115]
16-13	1828-1832	with	abstract[112]|abstract[114]|person[115]	new[112]|giv[114]|giv[115]	_	_
16-14	1833-1836	DPN	abstract[112]|abstract[114]|person[115]|abstract	new[112]|giv[114]|giv[115]|giv	coref	18-6[124_0]
16-15	1837-1842	after	_	_	_	_
16-16	1843-1847	they	person	giv	coref	33-4[239_0]
16-17	1848-1852	were	_	_	_	_
16-18	1853-1860	treated	_	_	_	_
16-19	1861-1865	with	_	_	_	_
16-20	1866-1867	a	event[119]	giv[119]	_	_
16-21	1868-1876	pancreas	object|event[119]	giv|giv[119]	_	_
16-22	1877-1887	transplant	event[119]	giv[119]	_	_
16-23	1888-1889	.	_	_	_	_

#Text=However , discrepancies exist in the time of response .
17-1	1890-1897	However	_	_	_	_
17-2	1898-1899	,	_	_	_	_
17-3	1900-1913	discrepancies	abstract	new	_	_
17-4	1914-1919	exist	_	_	_	_
17-5	1920-1922	in	_	_	_	_
17-6	1923-1926	the	abstract[121]	new[121]	_	_
17-7	1927-1931	time	abstract[121]	new[121]	_	_
17-8	1932-1934	of	abstract[121]	new[121]	_	_
17-9	1935-1943	response	abstract[121]|event	new[121]|new	_	_
17-10	1944-1945	.	_	_	_	_

#Text=Pharmacological treatment is used for painful DPN manifested as numbness , burning , stabbing , or excruciating or intractable pain ; only three treatments are approved by the U.S. Food and Drug Administration for the pain associated with DPN , namely , pregabalin , tapentadol , and duloxetine .
18-1	1946-1961	Pharmacological	abstract[123]	giv[123]	coref	26-6[199_123]
18-2	1962-1971	treatment	abstract[123]	giv[123]	_	_
18-3	1972-1974	is	_	_	_	_
18-4	1975-1979	used	_	_	_	_
18-5	1980-1983	for	_	_	_	_
18-6	1984-1991	painful	abstract[124]	giv[124]	coref	18-39[0_124]
18-7	1992-1995	DPN	abstract[124]	giv[124]	_	_
18-8	1996-2006	manifested	_	_	_	_
18-9	2007-2009	as	_	_	_	_
18-10	2010-2018	numbness	_	_	_	_
18-11	2019-2020	,	_	_	_	_
18-12	2021-2028	burning	_	_	_	_
18-13	2029-2030	,	_	_	_	_
18-14	2031-2039	stabbing	_	_	_	_
18-15	2040-2041	,	_	_	_	_
18-16	2042-2044	or	_	_	_	_
18-17	2045-2057	excruciating	_	_	_	_
18-18	2058-2060	or	_	_	_	_
18-19	2061-2072	intractable	abstract[125]	new[125]	coref	18-35[128_125]
18-20	2073-2077	pain	abstract[125]	new[125]	_	_
18-21	2078-2079	;	_	_	_	_
18-22	2080-2084	only	_	_	_	_
18-23	2085-2090	three	abstract[126]	giv[126]	coref	27-3[0_126]
18-24	2091-2101	treatments	abstract[126]	giv[126]	_	_
18-25	2102-2105	are	_	_	_	_
18-26	2106-2114	approved	_	_	_	_
18-27	2115-2117	by	_	_	_	_
18-28	2118-2121	the	object[127]	new[127]	_	_
18-29	2122-2126	U.S.	object[127]	new[127]	_	_
18-30	2127-2131	Food	object[127]	new[127]	_	_
18-31	2132-2135	and	_	_	_	_
18-32	2136-2140	Drug	_	_	_	_
18-33	2141-2155	Administration	_	_	_	_
18-34	2156-2159	for	_	_	_	_
18-35	2160-2163	the	abstract[128]	giv[128]	coref	20-22[0_128]
18-36	2164-2168	pain	abstract[128]	giv[128]	_	_
18-37	2169-2179	associated	_	_	_	_
18-38	2180-2184	with	_	_	_	_
18-39	2185-2188	DPN	abstract	giv	coref	23-16
18-40	2189-2190	,	_	_	_	_
18-41	2191-2197	namely	substance[130]	new[130]	_	_
18-42	2198-2199	,	substance[130]	new[130]	_	_
18-43	2200-2210	pregabalin	substance[130]	new[130]	_	_
18-44	2211-2212	,	_	_	_	_
18-45	2213-2223	tapentadol	substance	new	_	_
18-46	2224-2225	,	_	_	_	_
18-47	2226-2229	and	_	_	_	_
18-48	2230-2240	duloxetine	substance	new	_	_
18-49	2241-2242	.	_	_	_	_

#Text=Another pharmacological therapy includes analgesics , such as tramadol , acetaminophen , and some opioids such as oxycodone , which have constipation and nausea as side effects , and must be taken with care because they can be misused .
19-1	2243-2250	Another	abstract[133]	giv[133]	coref	29-9[216_133]
19-2	2251-2266	pharmacological	abstract[133]	giv[133]	_	_
19-3	2267-2274	therapy	abstract[133]	giv[133]	_	_
19-4	2275-2283	includes	_	_	_	_
19-5	2284-2294	analgesics	abstract[134]	new[134]	_	_
19-6	2295-2296	,	abstract[134]	new[134]	_	_
19-7	2297-2301	such	abstract[134]	new[134]	_	_
19-8	2302-2304	as	abstract[134]	new[134]	_	_
19-9	2305-2313	tramadol	abstract[134]|substance	new[134]|new	_	_
19-10	2314-2315	,	abstract[134]	new[134]	_	_
19-11	2316-2329	acetaminophen	abstract[134]|substance	new[134]|new	_	_
19-12	2330-2331	,	abstract[134]	new[134]	_	_
19-13	2332-2335	and	abstract[134]	new[134]	_	_
19-14	2336-2340	some	abstract[134]|substance[137]	new[134]|new[137]	_	_
19-15	2341-2348	opioids	abstract[134]|substance[137]	new[134]|new[137]	_	_
19-16	2349-2353	such	abstract[134]|substance[137]	new[134]|new[137]	_	_
19-17	2354-2356	as	abstract[134]|substance[137]	new[134]|new[137]	_	_
19-18	2357-2366	oxycodone	abstract[134]|substance[137]|substance	new[134]|new[137]|new	_	_
19-19	2367-2368	,	_	_	_	_
19-20	2369-2374	which	_	_	_	_
19-21	2375-2379	have	_	_	_	_
19-22	2380-2392	constipation	abstract|abstract[140]	new|new[140]	ana|ana	19-36[0_140]|19-36[0_140]
19-23	2393-2396	and	abstract[140]	new[140]	_	_
19-24	2397-2403	nausea	abstract[140]|abstract[141]	new[140]|new[141]	_	_
19-25	2404-2406	as	abstract[140]|abstract[141]	new[140]|new[141]	_	_
19-26	2407-2411	side	abstract[140]|abstract[141]|abstract	new[140]|new[141]|new	_	_
19-27	2412-2419	effects	abstract[140]|abstract[141]	new[140]|new[141]	_	_
19-28	2420-2421	,	_	_	_	_
19-29	2422-2425	and	_	_	_	_
19-30	2426-2430	must	_	_	_	_
19-31	2431-2433	be	_	_	_	_
19-32	2434-2439	taken	_	_	_	_
19-33	2440-2444	with	_	_	_	_
19-34	2445-2449	care	abstract	giv	_	_
19-35	2450-2457	because	_	_	_	_
19-36	2458-2462	they	abstract	giv	_	_
19-37	2463-2466	can	_	_	_	_
19-38	2467-2469	be	_	_	_	_
19-39	2470-2477	misused	_	_	_	_
19-40	2478-2479	.	_	_	_	_

#Text=Therapy with antidepressants such as amitriptyline , nortriptyline , and venlafaxine , among others , has shown an efficacy in neuropathic pain management .
20-1	2480-2487	Therapy	event[145]	new[145]	_	_
20-2	2488-2492	with	event[145]	new[145]	_	_
20-3	2493-2508	antidepressants	event[145]|substance[146]	new[145]|new[146]	_	_
20-4	2509-2513	such	event[145]|substance[146]	new[145]|new[146]	_	_
20-5	2514-2516	as	event[145]|substance[146]	new[145]|new[146]	_	_
20-6	2517-2530	amitriptyline	event[145]|substance[146]|substance	new[145]|new[146]|new	_	_
20-7	2531-2532	,	event[145]|substance[146]	new[145]|new[146]	_	_
20-8	2533-2546	nortriptyline	event[145]|substance[146]|substance	new[145]|new[146]|new	_	_
20-9	2547-2548	,	event[145]|substance[146]	new[145]|new[146]	_	_
20-10	2549-2552	and	event[145]|substance[146]	new[145]|new[146]	_	_
20-11	2553-2564	venlafaxine	event[145]|substance[146]|substance	new[145]|new[146]|new	_	_
20-12	2565-2566	,	_	_	_	_
20-13	2567-2572	among	_	_	_	_
20-14	2573-2579	others	_	_	_	_
20-15	2580-2581	,	_	_	_	_
20-16	2582-2585	has	_	_	_	_
20-17	2586-2591	shown	_	_	_	_
20-18	2592-2594	an	abstract[150]	new[150]	_	_
20-19	2595-2603	efficacy	abstract[150]	new[150]	_	_
20-20	2604-2606	in	abstract[150]	new[150]	_	_
20-21	2607-2618	neuropathic	abstract[150]|abstract[152]	new[150]|giv[152]	ana	21-1[0_152]
20-22	2619-2623	pain	abstract[150]|abstract|abstract[152]	new[150]|giv|giv[152]	_	_
20-23	2624-2634	management	abstract[150]|abstract[152]	new[150]|giv[152]	_	_
20-24	2635-2636	.	_	_	_	_

#Text=It has an effect on the recapture of noradrenaline and serotonin , as well as on muscarinic effects .
21-1	2637-2639	It	abstract	giv	_	_
21-2	2640-2643	has	_	_	_	_
21-3	2644-2646	an	abstract[154]	giv[154]	_	_
21-4	2647-2653	effect	abstract[154]	giv[154]	_	_
21-5	2654-2656	on	abstract[154]	giv[154]	_	_
21-6	2657-2660	the	abstract[154]|event[155]	giv[154]|new[155]	_	_
21-7	2661-2670	recapture	abstract[154]|event[155]	giv[154]|new[155]	_	_
21-8	2671-2673	of	abstract[154]|event[155]	giv[154]|new[155]	_	_
21-9	2674-2687	noradrenaline	abstract[154]|event[155]	giv[154]|new[155]	_	_
21-10	2688-2691	and	abstract[154]|event[155]	giv[154]|new[155]	_	_
21-11	2692-2701	serotonin	abstract[154]|event[155]|substance	giv[154]|new[155]|new	_	_
21-12	2702-2703	,	_	_	_	_
21-13	2704-2706	as	_	_	_	_
21-14	2707-2711	well	_	_	_	_
21-15	2712-2714	as	_	_	_	_
21-16	2715-2717	on	_	_	_	_
21-17	2718-2728	muscarinic	abstract[157]	new[157]	coref	24-11[174_157]
21-18	2729-2736	effects	abstract[157]	new[157]	_	_
21-19	2737-2738	.	_	_	_	_

#Text=In spite of this , there are limited studies evaluating these drugs because their doses in clinical trials are not entirely reproducible in clinical practice .
22-1	2739-2741	In	_	_	_	_
22-2	2742-2747	spite	_	_	_	_
22-3	2748-2750	of	_	_	_	_
22-4	2751-2755	this	_	_	_	_
22-5	2756-2757	,	_	_	_	_
22-6	2758-2763	there	_	_	_	_
22-7	2764-2767	are	_	_	_	_
22-8	2768-2775	limited	event[158]	giv[158]	_	_
22-9	2776-2783	studies	event[158]	giv[158]	_	_
22-10	2784-2794	evaluating	_	_	_	_
22-11	2795-2800	these	object[159]	new[159]	ana	22-14[0_159]
22-12	2801-2806	drugs	object[159]	new[159]	_	_
22-13	2807-2814	because	_	_	_	_
22-14	2815-2820	their	object|quantity[161]	giv|new[161]	coref|coref	29-12[217_161]|29-12[217_161]
22-15	2821-2826	doses	quantity[161]	new[161]	_	_
22-16	2827-2829	in	quantity[161]	new[161]	_	_
22-17	2830-2838	clinical	quantity[161]|abstract[162]	new[161]|new[162]	coref	24-1[172_162]
22-18	2839-2845	trials	quantity[161]|abstract[162]	new[161]|new[162]	_	_
22-19	2846-2849	are	_	_	_	_
22-20	2850-2853	not	_	_	_	_
22-21	2854-2862	entirely	_	_	_	_
22-22	2863-2875	reproducible	_	_	_	_
22-23	2876-2878	in	_	_	_	_
22-24	2879-2887	clinical	abstract[163]	new[163]	_	_
22-25	2888-2896	practice	abstract[163]	new[163]	_	_
22-26	2897-2898	.	_	_	_	_

#Text=Alpha-lipoic acid ( ALA ) has been suggested as a potential therapeutic agent in treating DPN ; its antioxidant capacity seems to delay or reverse damages to peripheral nerves .
23-1	2899-2911	Alpha-lipoic	substance[164]	new[164]	ana	23-18[0_164]
23-2	2912-2916	acid	substance[164]	new[164]	_	_
23-3	2917-2918	(	_	_	_	_
23-4	2919-2922	ALA	place	new	coref	24-14
23-5	2923-2924	)	_	_	_	_
23-6	2925-2928	has	_	_	_	_
23-7	2929-2933	been	_	_	_	_
23-8	2934-2943	suggested	_	_	_	_
23-9	2944-2946	as	_	_	_	_
23-10	2947-2948	a	_	_	_	_
23-11	2949-2958	potential	_	_	_	_
23-12	2959-2970	therapeutic	_	_	_	_
23-13	2971-2976	agent	_	_	_	_
23-14	2977-2979	in	_	_	_	_
23-15	2980-2988	treating	_	_	_	_
23-16	2989-2992	DPN	abstract	giv	coref	27-27
23-17	2993-2994	;	_	_	_	_
23-18	2995-2998	its	substance|abstract[169]	giv|new[169]	_	_
23-19	2999-3010	antioxidant	person|abstract[169]	new|new[169]	_	_
23-20	3011-3019	capacity	abstract[169]	new[169]	_	_
23-21	3020-3025	seems	_	_	_	_
23-22	3026-3028	to	_	_	_	_
23-23	3029-3034	delay	_	_	_	_
23-24	3035-3037	or	_	_	_	_
23-25	3038-3045	reverse	_	_	_	_
23-26	3046-3053	damages	abstract	new	_	_
23-27	3054-3056	to	_	_	_	_
23-28	3057-3067	peripheral	object[171]	new[171]	_	_
23-29	3068-3074	nerves	object[171]	new[171]	_	_
23-30	3075-3076	.	_	_	_	_

#Text=Several human randomized controlled trials ( RCTs ) have investigated the effects of ALA in the development of diabetic nephropathy .
24-1	3077-3084	Several	abstract[172]	giv[172]	_	_
24-2	3085-3090	human	abstract[172]	giv[172]	_	_
24-3	3091-3101	randomized	abstract[172]	giv[172]	_	_
24-4	3102-3112	controlled	abstract[172]	giv[172]	_	_
24-5	3113-3119	trials	abstract[172]	giv[172]	_	_
24-6	3120-3121	(	_	_	_	_
24-7	3122-3126	RCTs	event	new	coref	25-4[179_0]
24-8	3127-3128	)	_	_	_	_
24-9	3129-3133	have	_	_	_	_
24-10	3134-3146	investigated	_	_	_	_
24-11	3147-3150	the	abstract[174]	giv[174]	_	_
24-12	3151-3158	effects	abstract[174]	giv[174]	_	_
24-13	3159-3161	of	abstract[174]	giv[174]	_	_
24-14	3162-3165	ALA	abstract[174]|place	giv[174]|giv	ana	25-12
24-15	3166-3168	in	_	_	_	_
24-16	3169-3172	the	abstract[176]	new[176]	_	_
24-17	3173-3184	development	abstract[176]	new[176]	_	_
24-18	3185-3187	of	abstract[176]	new[176]	_	_
24-19	3188-3196	diabetic	abstract[176]|abstract[177]	new[176]|new[177]	_	_
24-20	3197-3208	nephropathy	abstract[176]|abstract[177]	new[176]|new[177]	_	_
24-21	3209-3210	.	_	_	_	_

#Text=A meta-analysis of four RCTs ( n = 653 ) showed that , compared with placebo , intravenous ALA ( 600 mg per day ) decreased symptoms of neuropathy when administered for three weeks , but symptom improvement with oral ALA ( >600 mg per day for 3 – 5 weeks ) was not clinically significant .
25-1	3211-3212	A	abstract[178]	new[178]	_	_
25-2	3213-3226	meta-analysis	abstract[178]	new[178]	_	_
25-3	3227-3229	of	abstract[178]	new[178]	_	_
25-4	3230-3234	four	abstract[178]|event[179]	new[178]|giv[179]	_	_
25-5	3235-3239	RCTs	abstract[178]|event[179]	new[178]|giv[179]	_	_
25-6	3240-3241	(	_	_	_	_
25-7	3242-3243	n	quantity	new	_	_
25-8	3244-3245	=	_	_	_	_
25-9	3246-3249	653	quantity	new	_	_
25-10	3250-3251	)	_	_	_	_
25-11	3252-3258	showed	_	_	_	_
25-12	3259-3263	that	place	giv	coref	25-18[184_0]
25-13	3264-3265	,	_	_	_	_
25-14	3266-3274	compared	_	_	_	_
25-15	3275-3279	with	_	_	_	_
25-16	3280-3287	placebo	substance	new	_	_
25-17	3288-3289	,	_	_	_	_
25-18	3290-3301	intravenous	place[184]	giv[184]	coref	25-40[192_184]
25-19	3302-3305	ALA	place[184]	giv[184]	_	_
25-20	3306-3307	(	_	_	_	_
25-21	3308-3311	600	quantity[185]	new[185]	coref	25-43[193_185]
25-22	3312-3314	mg	quantity[185]	new[185]	_	_
25-23	3315-3318	per	quantity[185]	new[185]	_	_
25-24	3319-3322	day	quantity[185]|time	new[185]|new	_	_
25-25	3323-3324	)	_	_	_	_
25-26	3325-3334	decreased	_	_	_	_
25-27	3335-3343	symptoms	abstract[187]	new[187]	_	_
25-28	3344-3346	of	abstract[187]	new[187]	_	_
25-29	3347-3357	neuropathy	abstract[187]|abstract	new[187]|giv	coref	28-25[214_0]
25-30	3358-3362	when	_	_	_	_
25-31	3363-3375	administered	_	_	_	_
25-32	3376-3379	for	_	_	_	_
25-33	3380-3385	three	time[189]	new[189]	coref	25-51[0_189]
25-34	3386-3391	weeks	time[189]	new[189]	_	_
25-35	3392-3393	,	_	_	_	_
25-36	3394-3397	but	_	_	_	_
25-37	3398-3405	symptom	abstract|abstract[191]	new|giv[191]	_	_
25-38	3406-3417	improvement	abstract[191]	giv[191]	_	_
25-39	3418-3422	with	abstract[191]	giv[191]	_	_
25-40	3423-3427	oral	abstract[191]|place[192]	giv[191]|giv[192]	_	_
25-41	3428-3431	ALA	abstract[191]|place[192]	giv[191]|giv[192]	_	_
25-42	3432-3433	(	_	_	_	_
25-43	3434-3438	>600	quantity[193]	giv[193]	_	_
25-44	3439-3441	mg	quantity[193]	giv[193]	_	_
25-45	3442-3445	per	quantity[193]	giv[193]	_	_
25-46	3446-3449	day	quantity[193]|time[194]	giv[193]|new[194]	_	_
25-47	3450-3453	for	quantity[193]|time[194]	giv[193]|new[194]	_	_
25-48	3454-3455	3	quantity[193]|time[194]|time[195]	giv[193]|new[194]|new[195]	_	_
25-49	3456-3457	–	quantity[193]|time[194]|time[195]	giv[193]|new[194]|new[195]	_	_
25-50	3458-3459	5	quantity[193]|time[194]|time[195]|quantity	giv[193]|new[194]|new[195]|new	_	_
25-51	3460-3465	weeks	quantity[193]|time[194]|time[195]|time	giv[193]|new[194]|new[195]|giv	_	_
25-52	3466-3467	)	_	_	_	_
25-53	3468-3471	was	_	_	_	_
25-54	3472-3475	not	_	_	_	_
25-55	3476-3486	clinically	_	_	_	_
25-56	3487-3498	significant	_	_	_	_
25-57	3499-3500	.	_	_	_	_

#Text=There is no evidence evaluating long-term treatment .
26-1	3501-3506	There	_	_	_	_
26-2	3507-3509	is	_	_	_	_
26-3	3510-3512	no	abstract[198]	new[198]	_	_
26-4	3513-3521	evidence	abstract[198]	new[198]	_	_
26-5	3522-3532	evaluating	_	_	_	_
26-6	3533-3542	long-term	abstract[199]	giv[199]	coref	30-8[225_199]
26-7	3543-3552	treatment	abstract[199]	giv[199]	_	_
26-8	3553-3554	.	_	_	_	_

#Text=Currently , treatments based on the use of mesenchymal stem cells ( MSC ) derived from adipose tissue have been considered as a potential treatment against DPN .
27-1	3555-3564	Currently	_	_	_	_
27-2	3565-3566	,	_	_	_	_
27-3	3567-3577	treatments	abstract	giv	coref	32-1[234_0]
27-4	3578-3583	based	_	_	_	_
27-5	3584-3586	on	_	_	_	_
27-6	3587-3590	the	abstract[201]	new[201]	_	_
27-7	3591-3594	use	abstract[201]	new[201]	_	_
27-8	3595-3597	of	abstract[201]	new[201]	_	_
27-9	3598-3609	mesenchymal	abstract[201]|animal|object[204]	new[201]|new|new[204]	appos|appos	27-13[0_204]|27-13[0_204]
27-10	3610-3614	stem	abstract[201]|plant|object[204]	new[201]|new|new[204]	_	_
27-11	3615-3620	cells	abstract[201]|object[204]	new[201]|new[204]	_	_
27-12	3621-3622	(	_	_	_	_
27-13	3623-3626	MSC	object	giv	_	_
27-14	3627-3628	)	_	_	_	_
27-15	3629-3636	derived	_	_	_	_
27-16	3637-3641	from	_	_	_	_
27-17	3642-3649	adipose	abstract|object[207]	new|new[207]	_	_
27-18	3650-3656	tissue	object[207]	new[207]	_	_
27-19	3657-3661	have	_	_	_	_
27-20	3662-3666	been	_	_	_	_
27-21	3667-3677	considered	_	_	_	_
27-22	3678-3680	as	_	_	_	_
27-23	3681-3682	a	_	_	_	_
27-24	3683-3692	potential	_	_	_	_
27-25	3693-3702	treatment	_	_	_	_
27-26	3703-3710	against	_	_	_	_
27-27	3711-3714	DPN	abstract	giv	coref	30-21
27-28	3715-3716	.	_	_	_	_

#Text=These therapies promote the production of pro-angiogenic , neuroprotective , and anti-inflammatory factors , which have a positive impact on the clinical manifestations of the disease .
28-1	3717-3722	These	abstract[209]	giv[209]	_	_
28-2	3723-3732	therapies	abstract[209]	giv[209]	_	_
28-3	3733-3740	promote	_	_	_	_
28-4	3741-3744	the	abstract[210]	new[210]	_	_
28-5	3745-3755	production	abstract[210]	new[210]	_	_
28-6	3756-3758	of	abstract[210]	new[210]	_	_
28-7	3759-3773	pro-angiogenic	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
28-8	3774-3775	,	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
28-9	3776-3791	neuroprotective	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
28-10	3792-3793	,	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
28-11	3794-3797	and	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
28-12	3798-3815	anti-inflammatory	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
28-13	3816-3823	factors	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
28-14	3824-3825	,	_	_	_	_
28-15	3826-3831	which	_	_	_	_
28-16	3832-3836	have	_	_	_	_
28-17	3837-3838	a	abstract[212]	new[212]	_	_
28-18	3839-3847	positive	abstract[212]	new[212]	_	_
28-19	3848-3854	impact	abstract[212]	new[212]	_	_
28-20	3855-3857	on	abstract[212]	new[212]	_	_
28-21	3858-3861	the	abstract[212]|abstract[213]	new[212]|new[213]	_	_
28-22	3862-3870	clinical	abstract[212]|abstract[213]	new[212]|new[213]	_	_
28-23	3871-3885	manifestations	abstract[212]|abstract[213]	new[212]|new[213]	_	_
28-24	3886-3888	of	abstract[212]|abstract[213]	new[212]|new[213]	_	_
28-25	3889-3892	the	abstract[212]|abstract[213]|abstract[214]	new[212]|new[213]|giv[214]	coref	32-3[236_214]
28-26	3893-3900	disease	abstract[212]|abstract[213]|abstract[214]	new[212]|new[213]|giv[214]	_	_
28-27	3901-3902	.	_	_	_	_

#Text=On the other hand , the use of biological therapy with low doses of IL-6 has been demonstrated to promote improvement of blood flow , decrease chronic inflammation , and regenerate peripheral nerve fibers .
29-1	3903-3905	On	_	_	_	_
29-2	3906-3909	the	_	_	_	_
29-3	3910-3915	other	_	_	_	_
29-4	3916-3920	hand	_	_	_	_
29-5	3921-3922	,	_	_	_	_
29-6	3923-3926	the	abstract[215]	new[215]	_	_
29-7	3927-3930	use	abstract[215]	new[215]	_	_
29-8	3931-3933	of	abstract[215]	new[215]	_	_
29-9	3934-3944	biological	abstract[215]|abstract[216]	new[215]|giv[216]	_	_
29-10	3945-3952	therapy	abstract[215]|abstract[216]	new[215]|giv[216]	_	_
29-11	3953-3957	with	abstract[215]	new[215]	_	_
29-12	3958-3961	low	abstract[215]|quantity[217]	new[215]|giv[217]	_	_
29-13	3962-3967	doses	abstract[215]|quantity[217]	new[215]|giv[217]	_	_
29-14	3968-3970	of	abstract[215]|quantity[217]	new[215]|giv[217]	_	_
29-15	3971-3975	IL-6	abstract[215]|quantity[217]|substance	new[215]|giv[217]|new	coref	30-3
29-16	3976-3979	has	_	_	_	_
29-17	3980-3984	been	_	_	_	_
29-18	3985-3997	demonstrated	_	_	_	_
29-19	3998-4000	to	_	_	_	_
29-20	4001-4008	promote	_	_	_	_
29-21	4009-4020	improvement	event[219]	new[219]	_	_
29-22	4021-4023	of	event[219]	new[219]	_	_
29-23	4024-4029	blood	event[219]|abstract[220]	new[219]|new[220]	coref	33-11[241_220]
29-24	4030-4034	flow	event[219]|abstract[220]	new[219]|new[220]	_	_
29-25	4035-4036	,	_	_	_	_
29-26	4037-4045	decrease	_	_	_	_
29-27	4046-4053	chronic	abstract[221]	new[221]	_	_
29-28	4054-4066	inflammation	abstract[221]	new[221]	_	_
29-29	4067-4068	,	_	_	_	_
29-30	4069-4072	and	_	_	_	_
29-31	4073-4083	regenerate	_	_	_	_
29-32	4084-4094	peripheral	object[223]	new[223]	_	_
29-33	4095-4100	nerve	abstract|object[223]	new|new[223]	coref	30-18
29-34	4101-4107	fibers	object[223]	new[223]	_	_
29-35	4108-4109	.	_	_	_	_

#Text=Accordingly , IL-6 may prove to be an effective treatment for the protection and/or restoration of peripheral nerve function in DPN ; see Table 1 .
30-1	4110-4121	Accordingly	_	_	_	_
30-2	4122-4123	,	_	_	_	_
30-3	4124-4128	IL-6	substance	giv	_	_
30-4	4129-4132	may	_	_	_	_
30-5	4133-4138	prove	_	_	_	_
30-6	4139-4141	to	_	_	_	_
30-7	4142-4144	be	_	_	_	_
30-8	4145-4147	an	abstract[225]	giv[225]	_	_
30-9	4148-4157	effective	abstract[225]	giv[225]	_	_
30-10	4158-4167	treatment	abstract[225]	giv[225]	_	_
30-11	4168-4171	for	abstract[225]	giv[225]	_	_
30-12	4172-4175	the	abstract[225]|abstract[226]	giv[225]|new[226]	_	_
30-13	4176-4186	protection	abstract[225]|abstract[226]	giv[225]|new[226]	_	_
30-14	4187-4193	and/or	abstract[225]|abstract[226]	giv[225]|new[226]	_	_
30-15	4194-4205	restoration	abstract[225]|abstract[226]|abstract[227]	giv[225]|new[226]|new[227]	_	_
30-16	4206-4208	of	abstract[225]|abstract[226]|abstract[227]	giv[225]|new[226]|new[227]	_	_
30-17	4209-4219	peripheral	abstract[225]|abstract[226]|abstract[227]|abstract[229]	giv[225]|new[226]|new[227]|new[229]	_	_
30-18	4220-4225	nerve	abstract[225]|abstract[226]|abstract[227]|abstract|abstract[229]	giv[225]|new[226]|new[227]|giv|new[229]	_	_
30-19	4226-4234	function	abstract[225]|abstract[226]|abstract[227]|abstract[229]	giv[225]|new[226]|new[227]|new[229]	_	_
30-20	4235-4237	in	abstract[225]|abstract[226]|abstract[227]|abstract[229]	giv[225]|new[226]|new[227]|new[229]	_	_
30-21	4238-4241	DPN	abstract[225]|abstract[226]|abstract[227]|abstract[229]|abstract	giv[225]|new[226]|new[227]|new[229]|giv	_	_
30-22	4242-4243	;	_	_	_	_
30-23	4244-4247	see	_	_	_	_
30-24	4248-4253	Table	abstract	new	_	_
30-25	4254-4255	1	quantity	new	_	_
30-26	4256-4257	.	_	_	_	_

#Text=4.2 .
31-1	4258-4261	4.2	abstract	new	_	_
31-2	4262-4263	.	_	_	_	_

#Text=Treatments for Peripheral Arterial Disease ( Ischemia )
32-1	4264-4274	Treatments	abstract[234]	giv[234]	_	_
32-2	4275-4278	for	abstract[234]	giv[234]	_	_
32-3	4279-4289	Peripheral	abstract[234]|abstract[236]	giv[234]|giv[236]	appos	32-7[0_236]
32-4	4290-4298	Arterial	abstract[234]|abstract|abstract[236]	giv[234]|new|giv[236]	_	_
32-5	4299-4306	Disease	abstract[234]|abstract[236]	giv[234]|giv[236]	_	_
32-6	4307-4308	(	_	_	_	_
32-7	4309-4317	Ischemia	abstract	giv	coref	33-1
32-8	4318-4319	)	_	_	_	_

#Text=Ischemia presenting in diabetic patients due to a reduction in blood flow that occurs in both small vessels ( microvascular , such as capillaries ) and large vessels ( macrovascular , such as arteries and veins ) , or due to a decrease of angiogenesis , can be treated through revascularization of at least one of the foot arteries to try to restore blood flow in patients with a DFU whose toe pressure is <30 mmHg or transcutaneous oxygen pressure ( TcPO2 ) <25 mmHg , as well as in those who have a DFU that does not heal with pressure on the ankle of <50 mmHg or ankle-brachial index ( ABI ) <0.5 .
33-1	4320-4328	Ischemia	abstract	giv	_	_
33-2	4329-4339	presenting	_	_	_	_
33-3	4340-4342	in	_	_	_	_
33-4	4343-4351	diabetic	person[239]	giv[239]	coref	33-67[256_239]
33-5	4352-4360	patients	person[239]	giv[239]	_	_
33-6	4361-4364	due	_	_	_	_
33-7	4365-4367	to	_	_	_	_
33-8	4368-4369	a	abstract[240]	new[240]	_	_
33-9	4370-4379	reduction	abstract[240]	new[240]	_	_
33-10	4380-4382	in	abstract[240]	new[240]	_	_
33-11	4383-4388	blood	abstract[240]|abstract[241]	new[240]|giv[241]	coref	33-64[255_241]
33-12	4389-4393	flow	abstract[240]|abstract[241]	new[240]|giv[241]	_	_
33-13	4394-4398	that	_	_	_	_
33-14	4399-4405	occurs	_	_	_	_
33-15	4406-4408	in	_	_	_	_
33-16	4409-4413	both	object[242]	new[242]	_	_
33-17	4414-4419	small	object[242]	new[242]	_	_
33-18	4420-4427	vessels	object[242]	new[242]	_	_
33-19	4428-4429	(	_	_	_	_
33-20	4430-4443	microvascular	abstract[243]	new[243]	_	_
33-21	4444-4445	,	abstract[243]	new[243]	_	_
33-22	4446-4450	such	abstract[243]	new[243]	_	_
33-23	4451-4453	as	abstract[243]	new[243]	_	_
33-24	4454-4465	capillaries	abstract[243]|object	new[243]|new	_	_
33-25	4466-4467	)	_	_	_	_
33-26	4468-4471	and	_	_	_	_
33-27	4472-4477	large	object[245]	new[245]	_	_
33-28	4478-4485	vessels	object[245]	new[245]	_	_
33-29	4486-4487	(	_	_	_	_
33-30	4488-4501	macrovascular	abstract[246]	new[246]	_	_
33-31	4502-4503	,	abstract[246]	new[246]	_	_
33-32	4504-4508	such	abstract[246]	new[246]	_	_
33-33	4509-4511	as	abstract[246]	new[246]	_	_
33-34	4512-4520	arteries	abstract[246]|object	new[246]|new	coref	33-57[254_0]
33-35	4521-4524	and	abstract[246]	new[246]	_	_
33-36	4525-4530	veins	abstract[246]|object	new[246]|new	_	_
33-37	4531-4532	)	_	_	_	_
33-38	4533-4534	,	_	_	_	_
33-39	4535-4537	or	_	_	_	_
33-40	4538-4541	due	_	_	_	_
33-41	4542-4544	to	_	_	_	_
33-42	4545-4546	a	abstract[249]	new[249]	_	_
33-43	4547-4555	decrease	abstract[249]	new[249]	_	_
33-44	4556-4558	of	abstract[249]	new[249]	_	_
33-45	4559-4571	angiogenesis	abstract[249]|abstract	new[249]|new	_	_
33-46	4572-4573	,	_	_	_	_
33-47	4574-4577	can	_	_	_	_
33-48	4578-4580	be	_	_	_	_
33-49	4581-4588	treated	_	_	_	_
33-50	4589-4596	through	_	_	_	_
33-51	4597-4614	revascularization	event[251]	new[251]	_	_
33-52	4615-4617	of	event[251]	new[251]	_	_
33-53	4618-4620	at	event[251]|object[252]	new[251]|new[252]	_	_
33-54	4621-4626	least	event[251]|object[252]	new[251]|new[252]	_	_
33-55	4627-4630	one	event[251]|object[252]	new[251]|new[252]	_	_
33-56	4631-4633	of	event[251]|object[252]	new[251]|new[252]	_	_
33-57	4634-4637	the	event[251]|object[252]|object[254]	new[251]|new[252]|giv[254]	_	_
33-58	4638-4642	foot	event[251]|object[252]|object|object[254]	new[251]|new[252]|new|giv[254]	_	_
33-59	4643-4651	arteries	event[251]|object[252]|object[254]	new[251]|new[252]|giv[254]	_	_
33-60	4652-4654	to	_	_	_	_
33-61	4655-4658	try	_	_	_	_
33-62	4659-4661	to	_	_	_	_
33-63	4662-4669	restore	_	_	_	_
33-64	4670-4675	blood	abstract[255]	giv[255]	_	_
33-65	4676-4680	flow	abstract[255]	giv[255]	_	_
33-66	4681-4683	in	_	_	_	_
33-67	4684-4692	patients	person[256]	giv[256]	_	_
33-68	4693-4697	with	person[256]	giv[256]	_	_
33-69	4698-4699	a	person[256]|abstract[257]	giv[256]|giv[257]	coref	33-94[265_257]
33-70	4700-4703	DFU	person[256]|abstract[257]	giv[256]|giv[257]	_	_
33-71	4704-4709	whose	person[256]|abstract[259]	giv[256]|new[259]	coref	33-75[260_259]
33-72	4710-4713	toe	person[256]|object|abstract[259]	giv[256]|new|new[259]	_	_
33-73	4714-4722	pressure	person[256]|abstract[259]	giv[256]|new[259]	_	_
33-74	4723-4725	is	person[256]	giv[256]	_	_
33-75	4726-4729	<30	person[256]|abstract[260]	giv[256]|giv[260]	coref	33-78[262_260]
33-76	4730-4734	mmHg	person[256]|abstract[260]	giv[256]|giv[260]	_	_
33-77	4735-4737	or	person[256]	giv[256]	_	_
33-78	4738-4752	transcutaneous	person[256]|abstract[262]	giv[256]|giv[262]	appos	33-82[0_262]
33-79	4753-4759	oxygen	person[256]|substance|abstract[262]	giv[256]|new|giv[262]	_	_
33-80	4760-4768	pressure	person[256]|abstract[262]	giv[256]|giv[262]	_	_
33-81	4769-4770	(	_	_	_	_
33-82	4771-4776	TcPO2	abstract	giv	coref	33-101[266_0]
33-83	4777-4778	)	_	_	_	_
33-84	4779-4782	<25	quantity[264]	new[264]	_	_
33-85	4783-4787	mmHg	quantity[264]	new[264]	_	_
33-86	4788-4789	,	quantity[264]	new[264]	_	_
33-87	4790-4792	as	quantity[264]	new[264]	_	_
33-88	4793-4797	well	quantity[264]	new[264]	_	_
33-89	4798-4800	as	quantity[264]	new[264]	_	_
33-90	4801-4803	in	quantity[264]	new[264]	_	_
33-91	4804-4809	those	quantity[264]	new[264]	_	_
33-92	4810-4813	who	_	_	_	_
33-93	4814-4818	have	_	_	_	_
33-94	4819-4820	a	abstract[265]	giv[265]	_	_
33-95	4821-4824	DFU	abstract[265]	giv[265]	_	_
33-96	4825-4829	that	_	_	_	_
33-97	4830-4834	does	_	_	_	_
33-98	4835-4838	not	_	_	_	_
33-99	4839-4843	heal	_	_	_	_
33-100	4844-4848	with	_	_	_	_
33-101	4849-4857	pressure	abstract[266]	giv[266]	_	_
33-102	4858-4860	on	abstract[266]	giv[266]	_	_
33-103	4861-4864	the	abstract[266]|object[267]	giv[266]|new[267]	_	_
33-104	4865-4870	ankle	abstract[266]|object[267]	giv[266]|new[267]	_	_
33-105	4871-4873	of	abstract[266]|object[267]	giv[266]|new[267]	_	_
33-106	4874-4877	<50	abstract[266]|object[267]	giv[266]|new[267]	_	_
33-107	4878-4882	mmHg	abstract[266]|object[267]	giv[266]|new[267]	_	_
33-108	4883-4885	or	abstract[266]|object[267]	giv[266]|new[267]	_	_
33-109	4886-4900	ankle-brachial	abstract[266]|object[267]|object[268]	giv[266]|new[267]|new[268]	_	_
33-110	4901-4906	index	abstract[266]|object[267]|object[268]	giv[266]|new[267]|new[268]	_	_
33-111	4907-4908	(	_	_	_	_
33-112	4909-4912	ABI	abstract	new	_	_
33-113	4913-4914	)	_	_	_	_
33-114	4915-4919	<0.5	abstract	new	_	_
33-115	4920-4921	.	_	_	_	_
